AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20417572
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three treatment groups
Trial: 18355330
Drug: Raisin consumption
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raisin consumption (90 g/day)
Trial: 16627548
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy plus placebo medication
Trial: 9103748
Drug: Anger treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anger treatment (12-session cognitive-behavioral treatment)
Trial: 3902480
Drug: GM1 ganglioside
RxNorm normalized name: Porcine GM1 ganglioside
DrugBank: Ganglioside GM1 (DB16948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM1 ganglioside (40 mg/day i.m. injection) for 6 weeks
Trial: 30172407
Drug: Cr supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cr supplementation (0.05 mg of Cr/kg of body weight0.75)
Trial: 30172407
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Cr supplement; Cr‐)
Trial: 27310977
Drug: Nitazoxanide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (500 mg bid), levofloxacin (500 mg once daily), omeprazole (40 mg bid), doxycycline (100 mg twice daily) for 14 days
Trial: 24902655
Drug: Individualized goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized goal-directed therapy (IGDT) with transthoracic echocardiography (TTE) and pulse-contour device (FloTrac™)
Trial: 24902655
Drug: Individualized goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized goal-directed therapy (IGDT)
Trial: 20816468
Drug: Antimigrainous medication
RxNorm normalized name: ANTIMIGRAINE AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimigrainous medication for treating single attacks and preventing recurring attacks
Trial: 10429625
Drug: Ifosfamide and
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide and continuous infusion of etoposide with growth factor
Trial: 10429625
Drug: Adjuvant ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant ifosfamide and doxorubicin treatment after primary surgery
Trial: 10429625
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for localized resectable STS
Trial: 8666123
Drug: Menorest® (adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menorest® (adhesive matrix transdermal system) used in combination with dydrogesterone for 12 days in each cycle
Trial: 8666123
Drug: Menorest® (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menorest® (twice weekly application)
Trial: 1869005
Drug: Iron medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron medication (2 x 1 Aktiferrin comp. Kps. during pregnancy starting from the 22nd week)
Trial: 1869005
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication during pregnancy (control group)
Trial: 6718333
Drug: Oxytocin (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (administered intravenously and/or intranasally)
Trial: 27411267
Drug: Compression dressing
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compression dressing therapy (observation group, n = 17)
Trial: 27411267
Drug: Ordinary dressing
RxNorm normalized name: ordinary salt combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary dressing therapy (control group, n = 17)
Trial: 22362859
Drug: Vilanterol trifenatate
RxNorm normalized name: Vilanterol Trifenatate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilanterol trifenatate (VI) 12.5-50 μg
Trial: 22362859
Drug: Vilanterol trifenatate
RxNorm normalized name: Vilanterol Trifenatate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilanterol trifenatate (VI) 3, 6.25, 12.5, 25 and 50 μg
Trial: 15825065
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral administration at 2-week intervals for 12 weeks)
Trial: 12614246
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist monotherapy (group 1)
Trial: 12614246
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist and chlormadinone acetate (group 2)
Trial: 1809525
Drug: 5% vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% vitamin E gel
Trial: 26983039
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with Tamsulosin plus Finasteride
Trial: 26983039
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with Tamsulosin
Trial: 23972722
Drug: 70 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 Gy salvage radiation therapy (RT)
Trial: 23972722
Drug: Dummy run
RxNorm normalized name: Run Guard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy run (DR) treatment plan for 70 Gy
Trial: 16644619
Drug: Ester-C (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ester-C (1000 mg)
Trial: 16644619
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic Acid (AA) (1000 mg)
Trial: 10662706
Drug: TPNGLN (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPNGLN (0.4 g x kg(‐1) x day(‐1))
Trial: 2001826
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole every morning
Trial: 6354100
Drug: AF (ADM,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AF (ADM, 40 mg/m2 q. 3W plus 5‐FUDS, 4 mg/kg daily)
Trial: 6354100
Drug: MF (MMC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF (MMC, 10 mg/m2 q. 3W plus 5‐FUDS, 4 mg/kg daily)
Trial: 30508988
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (RF lesions performed)
Trial: 30508988
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (no RF lesions performed)
Trial: 24697580
Drug: High IL-6-sR
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High IL-6-sR (≥ 37,401.36 pg/mL, highest tertile) at Year 16
Trial: 16009165
Drug: Cetrorelix acetate
RxNorm normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix acetate (3 mg SC)
Trial: 16009165
Drug: Ganirelix acetate
RxNorm normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganirelix acetate (0.25 mg SC daily)
Trial: 555598
Drug: Theolair SR
RxNorm normalized name: Theolair SR 250mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theolair SR (10 mg/kg)
Trial: 555598
Drug: Theo-Dur (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo-Dur (10 mg/kg)
Trial: 30653957
Drug: Netarsudil 0.02%
RxNorm normalized name: NETARSUDIL 0.02% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netarsudil 0.02% twice a day (b.i.d.)
Trial: 28732822
Drug: Beta-lactam monotherapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactam monotherapy continued
Trial: 11840581
Drug: Edrophonium 1
RxNorm normalized name: edrophonium 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1 mg/kg and atropine 0.01 mg/kg
Trial: 7625120
Drug: 160 RIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 RIA antigen unit dose
Trial: 1978161
Drug: daily injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily injections of growth hormone (rhGH) at 30 IU/m2 per week
Trial: 21709202
Drug: ASA404 (vadimezan)
RxNorm normalized name: Vadimézan
DrugBank: Vadimezan (DB06235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA404 (vadimezan) 1800 mg/m2, given intravenously once every 3 weeks for six cycles followed by maintenance ASA404
Trial: 21709202
Drug: ASA404 (vadimezan)
RxNorm normalized name: Vadimézan
DrugBank: Vadimezan (DB06235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA404 (vadimezan) 1800 mg/m2
Trial: 12527976
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g glucose (PLAC)
Trial: 12527976
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g glucose (LOW)
Trial: 12527976
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g glucose (MED)
Trial: 12527976
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g glucose (HIGH)
Trial: 10583700
Drug: Haloperidol 30
RxNorm normalized name: Haloperidol 300 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 30 mg/day plus Piracetam 3200 mg/day
Trial: 10583700
Drug: Haloperidol 30
RxNorm normalized name: Haloperidol 300 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 30 mg/day plus Placebo
Trial: 1988321
Drug: Ginger (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (1 g daily for 4 days)
Trial: 6874891
Drug: Dexamethasone phosphate
RxNorm normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone phosphate (5 mg each) at 12-h intervals for 4 injections
Trial: 26657041
Drug: e‐Learning +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e‐Learning + Workshop (e‐L + W)
Trial: 26657041
Drug: e‐Learning (e‐L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e‐Learning (e‐L)
Trial: 10591680
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride 60 mg/d
Trial: 10591680
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride 150 mg/d
Trial: 10591680
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEEs) 0.625 mg/d
Trial: 1661506
Drug: Cavinton (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavinton (additional to conventional therapy)
Trial: 6818707
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate 2 mg/ml
Trial: 6818707
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate 10 mg/ml
Trial: 6818707
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate 20 mg/ml
Trial: 6818707
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate 40 mg/ml
Trial: 27732083
Drug: Individualized acupuncture
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized acupuncture treatment (AT)
Trial: 25055057
Drug: Fresh rose
RxNorm normalized name: TITANIUM DIOXIDE 5.6 g in 100 mL TOPICAL LOTION [COOLA Rosilliance Mineral Tinted Face Moisturizer SPF 30 Fresh Rose]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh rose flowers as an olfactory stimulant
Trial: 10325836
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with piritramide 0.75 mg
Trial: 10325836
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with piritramide 1.5 mg
Trial: 1679316
Drug: Nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 300 mg daily
Trial: 6848648
Drug: Alcohol (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.1 ml/kg)
Trial: 11777833
Drug: Recombinant glycoprotein
RxNorm normalized name: Recombinant glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant glycoprotein (RGP) vaccines
Trial: 20372089
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated varicella-zoster virus (VZV) vaccine, two doses 12 weeks apart
Trial: 15916369
Drug: EHF‐IR therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHF‐IR therapy on biologically active points
Trial: 15916369
Drug: EHF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHF therapy alone
Trial: 12105828
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg intravenous bolus infusion, 20 minutes before endoscopy)
Trial: 9545623
Drug: Standard hypocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hypocaloric diet + ephedrine (2 x 25 mg) + caffeine (2 x 200 mg)
Trial: 9545623
Drug: Standard hypocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hypocaloric diet + ephedrine (2 x 25 mg) + caffeine (2 x 200 mg) + yohimbine (2 x 5 mg)
Trial: 20919
Drug: Rimiterol 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimiterol 0.5% (second dose 2h after first)
Trial: 20919
Drug: Rimiterol 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimiterol 0.5% (first dose)
Trial: 26289742
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol (FP/SAL) 100/50 mcg
Trial: 26289742
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 100 mcg
Trial: 8036686
Drug: Diethylcarbamazine (DEC)
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC) treatment
Trial: 17026651
Drug: Poria cocos
RxNorm normalized name: WOLFIPORIA COCOS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poria cocos (PoCo) applied in three concentrations in base cream DAC during the induction period of ICD.
Trial: 10954340
Drug: Gastric lavage
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric lavage (10x200 ml)
Trial: 9310272
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) infusion (120 microg/day) for 7 consecutive days
Trial: 3360973
Drug: 7432-S 25
RxNorm normalized name: (S)-2,5-Diaminopentanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7432-S 25 mg
Trial: 3360973
Drug: 7432-S 50
RxNorm normalized name: HYMETELLOSE (50 MPA.S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7432-S 50 mg
Trial: 3360973
Drug: 7432-S 100
RxNorm normalized name: ethylcellulose (100 MPA S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7432-S 100 mg
Trial: 3360973
Drug: 7432-S 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7432-S 200 mg
Trial: 3360973
Drug: 7432-S 100
RxNorm normalized name: ethylcellulose (100 MPA S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7432-S 100 mg twice daily for 2 weeks
Trial: 3360973
Drug: 7432-S 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7432-S 200 mg twice daily for 1 week
Trial: 3360973
Drug: 7432-S (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7432-S (all doses)
Trial: 31106840
Drug: Pre-treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment with antiplatelet drugs (acetylsalicylic acid 15 mg/kg, clopidogrel 11 mg/kg, ticagrelor 27 mg/kg, prasugrel 1.5 mg/kg)
Trial: 31106840
Drug: Pre-treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment with antiplatelet drugs
Trial: 31106840
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antiplatelet treatment)
Trial: 29753703
Drug: NGR-hTNF 0·8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGR-hTNF 0·8 μg/m2 intravenously plus best investigator choice (n=200)
Trial: 29753703
Drug: NGR-hTNF 0·8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGR-hTNF 0·8 μg/m2 intravenously
Trial: 17119469
Drug: Antioxidant vitamins
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamins and minerals (120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 microg selenium, 20 mg zinc)
Trial: 7957149
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Atenolol and Scopolamine
Trial: 2955007
Drug: Biperiden (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden (intravenous administration)
Trial: 31994405
Drug: Cycle ergometer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle ergometer training group (10-minute session, twice a day)
Trial: 29653208
Drug: Ixekizumab 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 120 mg, then 80 mg subcutaneously once every 4 weeks
Trial: 27470183
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (GTN) patch applied for 24 hours after surgery
Trial: 27470183
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch applied for 24 hours after surgery
Trial: 20852375
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid capsule, 1 g 3 times a day for 2 months
Trial: 18285430
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (twice-weekly classes and once-weekly independent exercise for three months)
Trial: 18285430
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (monitored monthly, management unchanged)
Trial: 3088219
Drug: Cisplatin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (120 mg/m2) plus Vindesine
Trial: 3088219
Drug: Cisplatin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (60 mg/m2) plus Vindesine plus Mitomycin C
Trial: 28786494
Drug: DBBM and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBBM and L‐PRF mixture (test)
Trial: 27409478
Drug: Aflibercept or
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept or ranibizumab intravitreal injections
Trial: 12814477
Drug: T-cell depleting
RxNorm normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell depleting antibody induction
Trial: 8855815
Drug: Estradiol 0.1
RxNorm normalized name: estradiol 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 0.1 mg/day transdermally
Trial: 1516394
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of furosemide following a single loading dose (LDCI)
Trial: 1516394
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous administration of furosemide (IA)
Trial: 3841410
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg pirenzepine
Trial: 3841410
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg pirenzepine twice daily
Trial: 3841410
Drug: 17.5 mg
RxNorm normalized name: acitretin 17.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 mg benzilonium bromide twice daily
Trial: 3841410
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg benzilonium bromide twice daily
Trial: 3841410
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg L-hyoscyamine twice daily
Trial: 29923955
Drug: 1.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL/kg lipid infusion (lipid group)
Trial: 9345448
Drug: BRB‐N tests
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRB‐N tests administered every 60 days for 120 days
Trial: 2264720
Drug: Cubital nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cubital nerve block with prilocaine (15 ml of 10 mg/ml)
Trial: 30704414
Drug: Standard heart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heart failure therapy